Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs today announced that they have entered into a worldwide, exclusive license agreement for Curis' Heat Shock Protein (Hsp90) technology, including CUDC-305, the company's lead Hsp90 inhibitor candidate.

Under the terms of the agreement, Debiopharm will assume all future development responsibility and incur all future costs related to the licensed Hsp90 technology, including CUDC-305. Curis currently expects that Debiopharm will file an application with health authorities to begin Phase I clinical testing for CUDC-305 in Fall 2009. Curis will receive an up-front license fee and, pending approval of such application, Curis will receive additional near-term payments. Curis is further eligible to receive additional contingent payments assuming the successful achievement of specified clinical development and regulatory approval objectives as well as royalties on product sales, if any, on any products that are successfully commercialised by Debiopharm or its sublicensees.

"We are very pleased to have entered into this license agreement with Debiopharm. We have been highly impressed with the depth of Debiopharm's development expertise and commitment to working with our team to create an optimum clinical development plan for our novel drug candidate, CUDC-305, which we believe may offer future benefit to cancer patients," said Dan Passeri, Curis President and Chief Executive Officer. "This transaction is particularly important to Curis because the agreement provides non-dilutive
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by ... the most dynamic collection of legal medical cannabis stories ever assembled. , ...
(Date:6/29/2015)... 2015   Pharnext SAS today announced that data ... treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in ... Nerve Society (PNS) Biennial Meeting at the Quebec Congress Center ... - July 2, 2015. At Poster Viewing Session ... 5p.m. to 7p.m. EDT: Poster 23: "A ...
(Date:6/29/2015)... ... ... The global microfluidics market is expected to grow at ... The market is mainly driven by the rising geriatric population, growing Asian healthcare ... adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals in ...
(Date:6/29/2015)... , June 29, 2015  AACC, a global ... health through laboratory medicine, is pleased to announce ... Clinical Chemistry , has increased to 7.9 in ... increase places Clinical Chemistry in the ... the significant influence of the research it publishes ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... AMSTERDAM, December 15, 2011 Amsterdam Molecular Therapeutics ... therapy, announced today that the Company has a negative equity ... of this negative equity position is in line with previous ... is exploring alternatives for additional financing. AMT announced ...
... discovery of a new way to tune and enhance thermal ... for a given material gives engineers a new tool ... and a number of other powered devices. The finding ... Li, associate professor of mechanical engineering at Vanderbilt University, and ...
... SHANGHAI, Dec. 14, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development outsourcing ... Morgan,s 30th Annual Healthcare Conference, to be held in ... Michael Xin Hui, founder and Chief Executive Officer of ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Announces Negative Equity Position 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 3New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 2New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 3
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... French . , Chicken sold in supermarkets, restaurants ... urinary tract infections (UTI), McGill researcher Amee Manges has discovered. ... in collaboration with the Public Health Agency of Canada and ... E. coli ( Escherichia coli ) bacteria originating from ...
... the first evidence from human research that blueberries ... other so-called phytochemicals improve memory. They said the ... to determine whether blueberries really deserve their growing reputation ... appears in ACS, Journal of Agricultural and Food ...
... a jury could decide a man,s guilt through mind reading? ... And what constitutes ,intent, to commit murder? These are ... inaugural issue of WIREs Cognitive Science, the latest interdisciplinary project ... the first two years. In the article "Neurolaw," ...
Cached Biology News:Retail meat linked to urinary tract infections: Strong new evidence 2Mind reading, brain fingerprinting and the law 2
... The nature of proteomics demands the ... The superior performance of the AXIMA-CFRplus with ... than 5 ppm) provides increased confidence in ... blanking for enhanced sensitivity, automated sample target ...
... Axima range, the AXIMA-CFR provides a ... sensitivity and mass range, and offers ... reflectron time-of-flight analysis. The unique patented ... of seamless PSD, providing efficient and ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
...
Biology Products: